Sight Sciences (SGHT)
NASDAQ:SGHT
US Market

Sight Sciences (SGHT) Stock Price & Analysis

50 Followers

SGHT Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$1.04 - $15.30
Previous Close$3.41
Volume1.06M
Average Volume (3M)467.65K
Market Cap
$163.31M
Enterprise Value$52.58M
Total Cash (Recent Filing)$144.50M
Total Debt (Recent Filing)$33.77M
Price to Earnings (P/E)-2.7
Beta2.07
Mar 21, 2024
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.27
Shares Outstanding48,749,876
10 Day Avg. Volume376,569
30 Day Avg. Volume467,651
Standard Deviation0.23
R-Squared0.12
Alpha-0.08
Financial Highlights & Ratios
Price to Book (P/B)1.31
Price to Sales (P/S)2.52
Price to Cash Flow (P/CF)-4.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue0.63
Enterprise Value/Gross Profit0.89
Enterprise Value/Ebitda-1.20
Forecast
Price Target Upside-2.35% Downside
Rating ConsensusHold
Number of Analyst Covering5


Financials

Annual

Ownership Overview

9.85% Mutual Funds
34.79% Other Institutional Investors
55.36% Public Companies and
Individual Investors

SGHT FAQ

What was Sight Sciences’s price range in the past 12 months?
Sight Sciences lowest stock price was $1.04 and its highest was $15.29 in the past 12 months.
    What is Sight Sciences’s market cap?
    Currently, no data Available
    When is Sight Sciences’s upcoming earnings report date?
    Sight Sciences’s upcoming earnings report date is Mar 21, 2024 which is in 111 days.
      How were Sight Sciences’s earnings last quarter?
      Sight Sciences released its earnings results on Nov 07, 2023. The company reported -$0.27 earnings per share for the quarter, beating the consensus estimate of -$0.318 by $0.048.
        Is Sight Sciences overvalued?
        According to Wall Street analysts Sight Sciences’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does Sight Sciences pay dividends?
          Sight Sciences does not currently pay dividends.
          What is Sight Sciences’s EPS estimate?
          Sight Sciences’s EPS estimate is -$0.33.
            How many shares outstanding does Sight Sciences have?
            Sight Sciences has 48,749,874 shares outstanding.
              What happened to Sight Sciences’s price movement after its last earnings report?
              Sight Sciences reported an EPS of -$0.27 in its last earnings report, beating expectations of -$0.318. Following the earnings report the stock price went down -1.905%.
                Which hedge fund is a major shareholder of Sight Sciences?
                Among the largest hedge funds holding Sight Sciences’s share is D1 Capital Partners LP. It holds Sight Sciences’s shares valued at 20M.

                  ---

                  Company Description

                  Sight Sciences

                  Sight Sciences Inc is a growth-stage medical device company transforming the two fastest growing segments in ophthalmology and optometry, glaucoma and dry eye disease. The company's product portfolio features the OMNI Surgical System, a dually-indicated device that facilitates the performance of both trabeculotomy and viscoelastic delivery. The company's non-surgical product portfolio consists of TearCare system which is commercially available for both ophthalmologists and optometrists.

                  ---

                  Top 5 ETFs holding SGHT

                  Name
                  Market Value
                  Smart Score
                  Vanguard Total Stock Market ETF
                  $1.37M
                  8
                  Fidelity MSCI Health Care Index ETF
                  $72.06K
                  8
                  Schwab U.S. Broad Market ETF
                  $47.83K
                  8
                  Vanguard Russell 3000 ETF
                  $1.71K
                  8
                  Dimensional US Core Equity 1 ETF
                  $34.10
                  8
                  Up to five ETFs with an Outperform Smart Score that hold SGHT. The ETFs are listed according to market value of SGHT within the ETF

                  Forecast EPS vs Actual EPS


                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  Kala Pharmaceuticals
                  Omeros
                  Ligand Pharma
                  G1 Therapeutics

                  Popular Stocks

                  ---
                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis